mRNA Manufacturing: In House Or Outsourced?
In this segment from the BioProcess Online Live event CMC, SCALE UP, & THE ROAD TO mRNA REGULATORY APPROVAL, Akhilesh Bhambhani, Sr. Director, Biologics Drug Product Development at Ultragenyx Pharmaceuticals and Roberta Duncan, VP and mRNA Program Lead at Seqirus share high-level manufacturing strategies for mRNA-based candidates in vaccine (Seqirus) and glycogen storage disease (Ultragenyx). Our panelists share what they’re manufacturing in house, what they’re outsourcing, and why.
VIEW THE VIDEO! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma X
Subscribe to Outsourced Pharma